Further investigation into the effects of IL-37 on the growth of oral cancer cells revealed that co-treatment of LPS and IL-37 resulted in a significant alleviation of the LPS-induced increase in cell viability for both HN13 and HSC-4 cells (Figure 2a and b). Here, IL37 is linked to lip and oral cavity carcinoma.